Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 15
---
, including our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, titled “Business,” “Risk Factors,” and “Operating and Financial Review and Prospects,” as well as other sections in this prospectus and the documents or reports incorporated by reference in this prospectus, including, for the avoidance of doubt, any “Supplemental Risk Factors” filed with our Form 6-Ks from time to time, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about:

| · | our requirement for additional financing and our ability to continue as a going concern; |

| · | our estimates regarding losses, expenses, future revenues, capital requirements and needs for additional 
 financing;                                                                                               |

| · | our ability to successfully develop, test and partner with a licensee to manufacture or commercialize 
 our products;                                                                                         |

| · | the successful commercialization and manufacturing of our any future product we may commercialize or license; |

| · | the success and timing of our preclinical studies and clinical trials; |

| · | shifts in our business and commercial strategy; |

| · | the filing and timing of regulatory filings, including Investigational New Drug applications, with respect to any of our product candidates 
 and the receipt of any regulatory approvals;                                                                                                |

| · | the anticipated medical benefits of our product candidates; |

| · | the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling 
 under any approval we may obtain;                                                                             |

| · | the success and timing of the potential commercial development of our product candidates and any product 
 candidates we may acquire in the future, including eRapa, tolimidone and MTX110;                         |

| · | our plans and ability to develop and commercialize our product candidates and any product candidates we 
 may acquire in the future;                                                                              |

| · | the ability to manufacture products in third-party facilities; |

| · | the rate and degree of market acceptance of any of our product candidates; |

| · | the successful development of our commercialization capabilities, including our internal sales and marketing 
 capabilities;                                                                                                |

| · | obtaining and maintaining intellectual property protection for our product candidates and our proprietary 
 technology;                                                                                               |

| · | the success of competing therapies and products that are or become available; |

| · | the success of any future acquisitions or other strategic transactions; |

| · | the difficulties of integrating the business of any future